Combination therapy for cancer: using immunotherapy and viruses 

How are scientists incorporating oncolytic viruses into the current cancer treatment landscape? 

While immunotherapy activates the immune system against cancer cells, its efficacy varies among patients. Oncolytic viruses selectively infect cancer cells and induce immunogenic cell death, making them an appealing adjunctive approach to enhance therapeutic responses. However, translating research findings into clinical success has been challenging. In this webinar, Howard Kaufman will discuss the current treatment landscape, challenges, and promising strategies for using oncolytic viruses in combination therapy for cancer. 

Topics to be covered

  • Clinical and logistical challenges of using oncolytic viruses
  • New strategies for combining oncolytic viruses and cancer immunotherapy

Thursday, April 18th, 2024 | 1:00 PM - 2:00 PM Eastern Time
This webinar will be available to view live and on demand.


Howard L. Kaufman, MD

Howard L. Kaufman, MD

President and CEO, Ankyra Therapeutics
Clinical Associate, Massachusetts General Hospital

Supported by